相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Christopher Tehlirian et al.
LANCET RHEUMATOLOGY (2021)
Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation
Lei Zhang et al.
CELL PROLIFERATION (2020)
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
Pablo Olivera et al.
GASTROENTEROLOGY (2020)
Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
Sascha Gerdes et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth B. Forman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Brian S. Gerstenberger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials
Feng Huang et al.
CLINICAL RHEUMATOLOGY (2019)
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh et al.
DRUG SAFETY (2019)
A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function
L. C. S. De Vries et al.
INFLAMMATORY BOWEL DISEASES (2019)
Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis
A. Mourad et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone et al.
JOURNAL OF RHEUMATOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials
Seth T. Howell et al.
ANNALS OF PHARMACOTHERAPY (2018)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier et al.
BMC RHEUMATOLOGY (2018)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database
Jin Yong Lee et al.
ANNALS OF DERMATOLOGY (2017)
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production
T. S. Mitchell et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
N. Punwani et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Herve Bachelez et al.
LANCET (2015)
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis
Sara C. Meyer et al.
BLOOD (2014)
Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia
Jean Grisouard et al.
HAEMATOLOGICA (2014)
Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis
Melissa G. Works et al.
JOURNAL OF IMMUNOLOGY (2014)
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
P. L. Mattei et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
The economic burden of psoriasis: a systematic literature review
Steven R. Feldman et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2014)
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
B. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Canadian Guidelines for the Management of Plaque Psoriasis: Overview
Kim Papp et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2011)
Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo
Masayuki Ishizaki et al.
JOURNAL OF IMMUNOLOGY (2011)
STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice
Mi-La Cho et al.
JOURNAL OF IMMUNOLOGY (2006)
Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function
K Shimoda et al.
IMMUNITY (2000)
分享论文
